Merck & Company (MRK) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Merck & Company (MRK)

130.20

+0.41 (0.32%)

as of Jul 31, 2026, 8:00:00 pm Market Open.

311 watching

Investor Insights

Aug 2, 2026, 12:00 am

This summary was created by AI, based on 23 opinions in the last 12 months.

Merck & Company (MRK) is recognized for its strong performance, particularly bolstered by its cancer treatment drug, Keytruda, which is a significant revenue driver but faces a looming patent cliff. Despite concerns regarding the future of Keytruda, many experts are optimistic about the company's robust drug pipeline and strategic acquisitions that should help mitigate the risks associated with the loss of this key drug. The consensus among analysts suggests solid revenue growth potential, with expectations that the company will release a considerable number of new drugs by 2030. Additionally, Merck is committed to returning capital to shareholders, which includes stock buybacks and steady dividends, positioning the company as a quality investment in the healthcare sector.

Consensus

Positive

Valuation

Undervalued

Similar

Pfizer, PFE

BUY

Great valuation and a good entry point.

DON'T BUY

Would prefer Pfizer (PFE-N) which has a far superior pipeline.

BUY

Big issue has been VIOXX. Very convoluted over the near term as to what will happen. Don't know what the legal issues will be. There could be more bad news from previous users of the drug. Have lots of money. Trades at almost 20% discount to the peer group. Nearly 5% yield. Has room for upside. Won't be an easy road.

WEAK BUY

Thinks it's going to be very tough to legally get this company with VIOXX. They have it as the 11th position in their portfolio. Model price is $38. Prefers Pfizer which has a bigger upside.

WEAK BUY

Feels they should have re-labelled rather than pulling Vioxx so that people would know how to use them properly. A huge number of lawsuits they could face down the road. Didn't grow by acquisition, so their pipeline looks a bit murky. A great company and will be around for a long time.

DON'T BUY

Companies like Pfizer and Merck have been coming apart for quite awhile. Growth rate has gone from 30% to low single digits. When this happens, the P/E has to contract. There are more sellers than buyers. One of the few that is doing better is Schering AG. Growth rate is accelerating and have a good line up of drugs.

DON'T BUY

Facing a large number of large and messy law suits.

WEAK BUY

Mispriced. Expects that down the road Vioxx will come back.

DON'T BUY

A cockroach company with one problem after another coming out of the woodwork.

DON'T BUY

In 2002, 2003 and early 2004 the chart looked like it was going to hold, but then collapsed. A broken down stock. Usually takes a significant amount of time for the news to be absorbed.

DON'T BUY

More aggressive than what they would want. A number of outstanding issues regarding litigation would keep the top executives eyes off running the business. Prefers Pfizer.

DON'T BUY

Market is pricing in $20/25 million for class action law suits, but it could be more. Would need a tremendous amount of earnings growth to reach what people are expecting and this is unlikeley. High dividend yield. No longer a safe story.

PAST TOP PICK

(A Top Pick July 12/04. Down 40%.) Sold out before the big drop.

BUY

Pharmaceuticals are cheaper than he has ever seen them. Cheap. Trading at low multiples.

DON'T BUY

Took a tremendous hit with their withdrawal of Vioxx. Buying it now would be bottom fishing. A lot of issues going on in the pharma sector now. Weak pipeline.

Showing 241 to 255 of 307 entries

Most Recent Experts

Amy Raskin, CIO, Chevy Chase Trust

Chevy Chase Trust

Stephanie Link, Chief investment strategist, Hightower

Hightower

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jim Lebenthal

Cerity Partners

Brianne Gardner

Raymond James

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Merck & Company (MRK)